BOOST.AI
25.11.2022 09:02:38 CET | Business Wire | Press release
Boost.ai, a Nordic Capital-backed global leader in conversational AI for enterprises, today announced that Jerry Haywood is joining the company’s executive team as Chief Executive Officer effective December 1, 2022. Haywood brings 20 years of enterprise technology experience with him and has held various sales and senior leadership positions at IBM, Cisco, and Salesforce. He joins Boost.ai from LivePerson, a global technology company that develops conversational commerce and AI software. Haywood will succeed founder and current CEO Lars Ropeid Selsås, who desires to devote more time to product development and innovation.
Selsås, who was actively involved in the selection process, alongside Co-Founder and Chief Commercial Officer Henry Vaage Iversen, and Chief Operating Officer Camilla Gjetvik, stated: “During this time of accelerated digital customer experience transformation, Boost.ai has never been better positioned to become a global category leader in conversational AI. This change in leadership is a natural step in the next growth phase for Boost.ai. Jerry is a strong and experienced visionary leader who can build on the solid foundation created over the last six years, and we are thrilled to have him join us. While it is his outstanding track record that made him a natural candidate for this key leadership role, it was his personality and people-oriented leadership style that impressed us most. He is approachable, humble, and full of energy. A natural leader who can create results while making it a fun ride.”
Vaage Iversen added: “I am very happy that Jerry has agreed to join the Boost.ai team as CEO and I'm glad that we are able to fulfil Lars’ desire to focus even more on what he is most passionate about - the technology needed to fundamentally disrupt the conversational AI category and to continue to provide the best automated customer interaction solution available on the market.”
For the last three years, Haywood has held the role of SVP EMEA at LivePerson, where he led the strategic repositioning of the company in Europe, achieving impressive growth. Prior to LivePerson, Haywood spent eight years at Salesforce, where he headed up Service Cloud first in the UK, and then for the rest of Europe, achieving an increase of over 30% in revenue and bookings year after year.
Haywood said: “I am really excited and honoured to join the Boost.ai team, at a time where the owners and leadership want to accelerate growth while positioning the company as a global category leader in the conversational AI space. Boost.ai is already very familiar to me. I have followed their amazing journey closely and I am convinced that the scale up has what it needs to go all the way. Boost.ai has the best technology available and an amazing team with some of the brightest minds in the industry. I want to thank the founders, the Board of Directors and Nordic Capital for their trust. I can't wait to meet the team across the globe and get started.”
Haywood will balance his time between Stavanger, Norway, where Boost.ai is headquartered, and London, UK, one of Boost.ai’s key markets, where he lives with his wife and three children.
About Boost.ai
Boost.ai specializes in enterprise-grade conversational artificial intelligence (AI). Inventor of the world’s most scalable conversational AI platform, Boost.ai empowers enterprises to automate customer service and internal support channels, enhance human efficiency, and drive revenue with proprietary self-learning AI and a no-code solution that’s quick to deploy, easy to learn and highly scalable. Learn more at boost.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221125005046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom